Plexure (ASX: PX1) gets another endorsement from Maccas

Nick Sundich Nick Sundich, August 1, 2022

Plexure (ASX: PX1) has been through a difficult time since listing, but got some respite this morning. The New Zealand-founded mobile engagement platform listed on the ASX in late 2020, having already listed on the NZX.  

When it listed, one of its key selling points to investors was that McDonalds backed it as a client and an investor – it owns just over 4% of the firm. This morning, the fast-food giant gave Plexure another endorsement.   

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

Who is Plexure? 

Plexure is a company that helps consumer brands deliver one on one offers through their mobile devices. These individual offers are designed to drive traffic to physical stores. In the 12 months to 31 March 2022, it achieved NZ$32.6m in revenue, but an EBITDA loss of $15.6m.  

Shares have suffered as investors turned away from non-profitable companies. Although McDonalds has backed the company, PX1 struggled to broaden its customer base. A merger with Australian group Task did little to help broaden its appeal, even though it won some notable deals – including with Accor Stadium in Sydney. 

 

plexure

Plexure (ASX:PX1) share price chart (Graph: TradingView)

 

Another deal from McDonalds and solid FY23 guidance 

But this morning, shares rose over 80% off the back of two pieces of goods news. First, McDonalds signed another 5-year contract with the company. And secondly, it gave guidance for FY23 which indicated profitability. For the year ending 31 March 2023, it is expecting NZ$56m in revenue, up over 70% from FY22, and $3.7m in positive EBITDA. 

Plexure is one of several companies that have been through one-day jumps after announcing that profitability was expected in the forthcoming financial year. But for companies such as Plexure, with a history of under-delivering, we would exercise caution until it actually achieves these results (at least on a half-yearly basis).  

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

Blog Categories

Get the Latest Insider Trades on ASX!

Recent Posts

These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Healthcare Stocks Benefiting From AI Artificial intelligence is reshaping healthcare faster than most investors realise. Hospital imaging systems, pathology…

Which ASX Uranium Stocks Benefit Most From the Iran War and the Hormuz Oil Crisis?

ASX Uranium Stocks to Watch This Week Brent crude is sitting just above US$111 a barrel as of this morning,…

Telix pharmaceuticals (ASX: TLX) A$230m Quarter Puts Guidance Back In Play

Is Telix in Turnaround Mode or Dead-Cat Bounce? The question investors are now asking about Telix pharmaceuticals is whether the…